

Garadacimab (andembry) approved to prevent angioedema attacks

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 24th January 2025, approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to prevent angioed...